Vinod P. Balachandran

Author

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Australian Pancreatic Cancer Genome Initiative, J Gui, V Balachandran, V. Balachandran, V. P. Balachandran, V.P. Balachandran, Vinod Balachandran, Vinod P Balachandran, Vinod P. Balachandran

437

Publications

16.3K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Weill Cornell Medicine Erasmus MC Cancer Institute Parker Institute for Cancer Immunotherapy

About

Vinod P. Balachandran is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	52	5.6K
2	Health Sciences	11	11	422
3	Engineering	3	3	79
4	Biostatistics	2	2	56
5	Natural Sciences	1	1	13

Vinod P. Balachandran

118

Publications

10.9K

Citations

H-Index

Page 1

	Year	Citations
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers Ayuko Hoshino, Han Sang Kim, Linda Bojmar, Cell Tumor BiologyExtracellular VesicleMedicinePathologyExtracellular Microvesicles	2020	1.2K
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer Luis A. Rojas, Zachary Sethna, Kevin C. Soares, Nature	2023	1.1K
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy Marta Łuksza, Nadeem Riaz, Vladimir Makarov, Nature Cancer ImmunosurveillanceTumour ResponseMedicineImmunologyNeoantigen Fitness Model	2017	647
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido Vinod P. Balachandran, Michael J. Cavnar, Shan Zeng, Nature Medicine Cancer ImmunosurveillanceGastrointestinal OncologyMedicineT-regulatory CellImmunology	2011	517
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors Cristina Valero, Mark Lee, Douglas R. Hoen, Nature Communications	2021	435
ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity John A. Moral, Joanne Leung, Luis A. Rojas, Nature Tumor ImmunologyCancer ImmunosurveillanceTissue-specific Cancer ImmunityImmunologyTumor Immunity	2020	327
The association between tumor mutational burden and prognosis is dependent on treatment context Cristina Valero, Mark Lee, Douglas R. Hoen, Nature Genetics Tumor Mutational BurdenTumor HeterogeneityMedicinePathologyCancer Genomics	2021	256
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types Diego Chowell, Seong‐Keun Yoo, Cristina Valero, Nature Biotechnology Cancer ImmunosurveillanceMedicineImmunologyMultiple Cancer TypesImmune Checkpoint Inhibitor	2021	254
Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? John M. Creasy, Eran Sadot, Bas Groot Koerkamp, Surgery Actual 10-Year SurvivalSurgical OncologyHepatologyColorectal Liver MetastasesGastrointestinal Oncology	2018	220
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection Wungki Park, Jiapeng Chen, Joanne F. Chou, Clinical Cancer Research	2020	214

Page 1